On February 9th, President Donald Trump made the following promise:
“We’re going to be announcing something over the next, I would say, two or three weeks that will be phenomenal in terms of tax.”
Now, say what you will about Trump’s presidency, but to date, he’s followed through on his promises. He said we’ll have a wall? We’re getting a wall. He said he’d keep terrorists out? He’s enacted sweeping — and potentially unconstitutional — immigration reform. Twice. He said he’d drain the swamp? He…well, two out of three ain’t bad.
But where’s the tax plan? Drastic individual and business tax cuts were a huge part of Trump successful campaign, but in the first 50 days of his presidency, he has produced nothing.
What’s the holdup?
U.S. President Donald Trump walks towards Marine One on the South Lawn of the White House in Washington, D.C., U.S., on Friday, March 3, 2017. Trump is traveling to Florida to par ticipate in a tour of Saint Andrew Catholic School and attend the RNC Spring Retreat dinner. Photographer: Andrew Harrer/Bloomberg
swing trading software: LaSalle Hotel Properties(LHO)
- [By Marshall Hargrave]
The other key benefit for Strategic is that it enjoys industry-leading earnings before interest, taxes, depreciation and amortization (EBITDA) per available room. For 2012, Strategic generated $81 per room of EBITDA. Compare this to top comps LaSalle Hotel (NYSE: LHO) at $74 per room and Pebblebrook Hotel Trust (NYSE: PEB) at $71. The reason for this is that Strategic is much less reliant than its peers on rooms, with much greater exposure to food and beverages. Strategic earns 53% of its revenue from rooms, while its peers get around 66% of revenues from rooms.
swing trading software: Cotiviti Holdings, Inc. (COTV)
- [By Scott Rubin]
Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.
swing trading software: Sanofi(SNY)
- [By Sean Williams]
MannKind has just one Food and Drug Administration-approved therapy, an inhalable type 1 and type 2 diabetes drug known as Afrezza. On paper Afrezza looked like a winner. It was fast-acting, it metabolized through the body more quickly than traditional insulin, and it was exceptionally convenient since there were no needles involved. The company also wound up licensing the drug out to Sanofi (NYSE:SNY) in 2014, netting much needed upfront capital and help on the expenses front.
- [By Chris Lange]
Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.
- [By Todd Campbell]
Biogen’s suite of MS drugs makes it the biggest maker of multiple sclerosis drugs, by market share, but Teva Pharmaceutical, Novartis (NYSE:NVS), and Sanofi SA (NYSE:SNY) are also racking up billions in sales annually in the indication.
- [By Brian Feroldi]
Shares of Flexion Therapeutics (NASDAQ:FLXN) rose by more than 33% at$26.28 in Thursday trading, in response to rumors that a takeover bid from Sanofi (NYSE:SNY) is looming.
- [By Money Morning Staff Reports]
The drug is currently in phase 1 of an extensive trial, after which the U.S. Department of Health and Human Services (DHHS) will pass the vaccine on to French pharmaceutical company Sanofi SA (NYSE ADR: SNY). Sanofi will carry out the vaccine’s phase 2 and phase 3 trials because “of the high risk and high costs involved in advanced vaccine development,” the Army wrote in an April 21 public letter on its website.
- [By Emily Stewart]
Paulson picked up 395,500 shares of Sanofi SA (SNY) valued at $16.6 million.
Sanofi is a health care company engaged in the research, development, manufacture and marketing of healthcare products. It has a $101.4 billion market cap and trades at a P/E of 21.18.
swing trading software: EnLink Midstream Partners, LP(ENLK)
- [By WWW.MONEYSHOW.COM]
EnLink Midstream Partners (ENLK) is sponsored by independent oil and gas exploration giant Devon Energy (DVN), the owner of this acreage.
These basins offer superior economics and EnLink’s close relationship with Devon provides leveraged exposure to the upstream operator’s accelerating activity in these plays.
swing trading software: Skyworks Solutions, Inc.(SWKS)
- [By WWW.MONEYSHOW.COM]
We also favor Skyworks Solutions (SWKS), a previous winner in our model portfolio which is expected to end its recent earnings slump in 2017 following the Apple (AAPL), long a staple among our stock picks, has just spurted ahead again. Once as high as $132, it slumped to $90 in 2015 on growth skepticism.
- [By Arie Goren]
Semiconductor companies have done very well in the last year. In fact, in the last 52 weeks, the average price change for the sixteen semiconductor stocks which are included in the S&P 500 index was 35.62%. In this period the price change of the S&P 500 was 11.94%, and of the Nasdaq Composite Index was 8.99%. Moreover, only two S&P 500 semiconductor companies Skyworks Solutions (NSDQ:SWKS)and First Solar (NSDQ:FSLR)have seen their stock prices decline in the last 52 weeks.
- [By Harsh Chauhan]
More importantly, Apple could build around 120 million new iPhones this year as compared to 89 million units of the iPhone 7/7S in 2016 — according to Mizuho. This is great news for the other companies in Cupertino’s supply chain — such as Skyworks Solutions (NASDAQ:SWKS), Broadcom (NASDAQ:AVGO), and Cypress Semiconductor (NASDAQ:CY) — as they won’t have to wait until the second half of the year to bask in iPhone-driven glory.